CN110606841A - 吡啶胺基嘧啶衍生物的晶型及其制备方法 - Google Patents
吡啶胺基嘧啶衍生物的晶型及其制备方法 Download PDFInfo
- Publication number
- CN110606841A CN110606841A CN201810626680.6A CN201810626680A CN110606841A CN 110606841 A CN110606841 A CN 110606841A CN 201810626680 A CN201810626680 A CN 201810626680A CN 110606841 A CN110606841 A CN 110606841A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- crystallization
- solvent
- cooling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810626680.6A CN110606841A (zh) | 2018-06-15 | 2018-06-15 | 吡啶胺基嘧啶衍生物的晶型及其制备方法 |
PCT/CN2019/091181 WO2019238102A1 (zh) | 2018-06-15 | 2019-06-14 | 吡啶胺基嘧啶衍生物的晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810626680.6A CN110606841A (zh) | 2018-06-15 | 2018-06-15 | 吡啶胺基嘧啶衍生物的晶型及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110606841A true CN110606841A (zh) | 2019-12-24 |
Family
ID=68842727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810626680.6A Pending CN110606841A (zh) | 2018-06-15 | 2018-06-15 | 吡啶胺基嘧啶衍生物的晶型及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110606841A (zh) |
WO (1) | WO2019238102A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240043405A1 (en) * | 2020-03-23 | 2024-02-08 | Dana-Farber Cancer Institute, Inc. | Potent and selective irreversible inhibitors of irak1 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315259A (zh) * | 2014-07-29 | 2016-02-10 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
CN107163026A (zh) * | 2016-03-07 | 2017-09-15 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
CN107163027A (zh) * | 2016-03-07 | 2017-09-15 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
-
2018
- 2018-06-15 CN CN201810626680.6A patent/CN110606841A/zh active Pending
-
2019
- 2019-06-14 WO PCT/CN2019/091181 patent/WO2019238102A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315259A (zh) * | 2014-07-29 | 2016-02-10 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
CN107163026A (zh) * | 2016-03-07 | 2017-09-15 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
CN107163027A (zh) * | 2016-03-07 | 2017-09-15 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
Non-Patent Citations (2)
Title |
---|
方亮: "《药剂学(第3版)》", 31 March 2016, 中国医药科技出版社 * |
赵桂森: "《新药设计与开发基础》", 30 November 2015, 山东大学出版社 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019238102A1 (zh) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102075371B1 (ko) | 퀴놀린 유도체 제조 방법 | |
EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
KR102078077B1 (ko) | 타이로신 키나제 억제제 다이말리에이트의 결정형 아이 및 그의 제조 방법 | |
CN110818633A (zh) | 一种苹果酸盐及其晶型 | |
WO2011095059A1 (zh) | 达沙替尼多晶型物及其制备方法和药物组合物 | |
WO2014016848A2 (en) | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof | |
WO2013175483A1 (en) | Process for preparing crystalline sorafenib tosylate | |
AU2016239028B2 (en) | P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor | |
CA2958741C (en) | Quinazoline derivatives | |
CN114751891B (zh) | 一种(2-(1h-吲哚-3-基)-1h-咪唑-4-基)苯基甲酮类化合物及其应用 | |
CA2134630A1 (en) | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives | |
EP3665176B1 (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
US9453011B2 (en) | Crystal form of dabrafenib mesylate and preparation method thereof | |
WO2015068055A1 (en) | Crystalline dasatinib process | |
CN110606841A (zh) | 吡啶胺基嘧啶衍生物的晶型及其制备方法 | |
US10464946B2 (en) | Crystalline forms of thienopyrimidine compound | |
EP3322709B1 (en) | Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof | |
KR20220016949A (ko) | Cdk9 억제제의 결정다형 및 이의 제조방법과 용도 | |
AU2018286057B2 (en) | 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof | |
CN111732586B (zh) | 含炔基化合物盐的晶型、制备方法及应用 | |
WO2020119772A1 (zh) | 盐酸美呋哌瑞多晶型物及其制备方法 | |
AU2016361026B2 (en) | Method for purifying benzopyran derivative, crystal form thereof, and method for preparing crystal form | |
CN110964017A (zh) | 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途 | |
CN110627777B (zh) | 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途 | |
RU2783418C9 (ru) | Способ получения полиморфа гидрохлорида 2-[4-(метиламинометил)фенил]-5-фтор-бензофуран-7-карбоксамида |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 201203, Zhangjiang hi tech park, Shanghai, Harley Road, No. 5, building 1118 Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc Address before: 201203, 5 floor, 1118 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Applicant before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201203 floor 5, building 1, No. 1227, zhangheng Road, free trade zone, Pudong New Area, Shanghai Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc Address before: 201203 5th floor, No. 1118, Halley Road, Zhangjiang hi tech park, Shanghai Applicant before: Shanghai ALLIST medicine Polytron Technologies Inc |
|
CB02 | Change of applicant information | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40015587 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191224 |
|
RJ01 | Rejection of invention patent application after publication |